Regensburg, February 02, 2021. The market for tablets with highly active ingredients, such as those in cytostatics, immunosuppressants or hormone-containing products, is growing rapidly. This development places the highest demands on production as well as on personnel safety. As a leading contract manufacturer for the pharmaceutical and healthcare industry, the Aenova Group also produces in the area of these so-called HPAPIs (High Potency Active Pharmaceutical Ingredients).